Provided by Tiger Trade Technology Pte. Ltd.

Foghorn Therapeutics Inc.

5.45
-0.2300-4.05%
Post-market: 5.450.00000.00%17:57 EST
Volume:117.70K
Turnover:643.21K
Market Cap:319.27M
PE:-4.76
High:5.66
Open:5.64
Low:5.40
Close:5.68
52wk High:6.95
52wk Low:2.94
Shares:58.58M
Float Shares:28.87M
Volume Ratio:0.62
T/O Rate:0.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1460
EPS(LYR):-1.5778
ROE:-470.38%
ROA:-21.07%
PB:-3.56
PE(LYR):-3.45

Loading ...

Foghorn Therapeutics to Present at Guggenheim Emerging Outlook Biotech Summit

Reuters
·
Feb 03

Press Release: Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium

Dow Jones
·
Jan 14

Analysts Are Bullish on Top Healthcare Stocks: Alnylam Pharma (ALNY), Foghorn Therapeutics (FHTX)

TIPRANKS
·
Jan 13

Press Release: Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Dow Jones
·
Jan 10

Foghorn Therapeutics Inc : Btig Initiates Coverage With Buy Rating; Target Price $11

THOMSON REUTERS
·
Dec 18, 2025

BTIG Research Initiates Coverage on Foghorn Therapeutics With Buy Rating, $11 Price Target

MT Newswires Live
·
Dec 18, 2025

Foghorn Therapeutics Initiated at Buy by BTIG

Dow Jones
·
Dec 18, 2025

Foghorn Therapeutics Initiated at Buy by Stifel

Dow Jones
·
Dec 05, 2025

Stifel Nicolaus Initiates Coverage on Foghorn Therapeutics With Buy Rating, $12 Price Target

MT Newswires Live
·
Dec 04, 2025

Foghorn Therapeutics Inc - on Dec 3, Appointed Jeff Sacher as Interim CFO - SEC Filing

THOMSON REUTERS
·
Dec 04, 2025

Foghorn Therapeutics Names Jeff Sacher Interim CFO

Reuters
·
Dec 04, 2025

Foghorn Therapeutics to Present at Evercore Healthcare Conference

Reuters
·
Nov 25, 2025

Foghorn Therapeutics Q3 EPS USD -0.25

Reuters
·
Nov 20, 2025

Foghorn Therapeutics Unveils Strategic Advancements with Lilly

TIPRANKS
·
Nov 08, 2025

Foghorn Therapeutics Initiated at Buy by Guggenheim

Dow Jones
·
Nov 08, 2025

Guggenheim Initiates Coverage on Foghorn Therapeutics With Buy Rating, $12 Price Target

MT Newswires Live
·
Nov 07, 2025

Foghorn Therapeutics: Promising Pipeline and Strategic Collaborations Drive Buy Rating

TIPRANKS
·
Nov 06, 2025

BRIEF-Foghorn Therapeutics Inc - On Oct 31, Kristian Humer Resigned As CFO Effective November 14, 2025 - SEC Filing

Reuters
·
Nov 05, 2025

Foghorn Therapeutics Q3 collaboration revenue rises, net loss narrows on Lilly partnership

Reuters
·
Nov 05, 2025

Foghorn Therapeutics Q3 EPS $(0.25) Beats $(0.30) Estimate, Sales $8.153M Beat $6.197M Estimate

Benzinga
·
Nov 05, 2025